Equities Analysts Offer Predictions for TNYA Q1 Earnings

Key Points

• Tenaya Therapeutics is predicted to report a Q1 2026 EPS of ($0.30), with full-year earnings estimated at ($1.35) per share according to William Blair.
• The company last reported earnings on May 7th, missing analysts' expectations by $0.06 with an EPS of ($0.24).
• Six analysts rated TNYA as a “buy” with an average price target of $6.25, while the stock currently trades at around $0.67.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Tenaya Therapeutics in a note issued to investors on Wednesday, July 30th. William Blair analyst S. Corwin forecasts that the company will post earnings of ($0.30) per share for the quarter. The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics' Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.20) EPS.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06).

A number of other analysts also recently commented on TNYA. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a report on Friday, April 25th. Chardan Capital restated a "buy" rating and set a $9.00 price objective on shares of Tenaya Therapeutics in a report on Friday, May 9th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $6.25.

Tenaya Therapeutics Stock Down 0.8%

TNYA stock opened at $0.67 on Monday. The company has a market cap of $109.09 million, a price-to-earnings ratio of -0.58 and a beta of 3.01. The business has a fifty day simple moving average of $0.64 and a 200-day simple moving average of $0.69. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $4.01.

Institutional Trading of Tenaya Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC acquired a new stake in Tenaya Therapeutics in the 4th quarter valued at $45,000. Northern Trust Corp increased its holdings in Tenaya Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 472,479 shares of the company's stock valued at $676,000 after purchasing an additional 27,632 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Tenaya Therapeutics in the 1st quarter valued at about $33,000. Deutsche Bank AG grew its stake in shares of Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company's stock valued at $185,000 after acquiring an additional 97,318 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its position in shares of Tenaya Therapeutics by 25.2% during the fourth quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company's stock worth $494,000 after acquiring an additional 69,377 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.